Meeting
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Therapeutic effects of 2B8T2M, a novel fusion of ALT-803, an IL-15 superagonist, with 4 single-chains of anti-CD20 antibody in combination with expanded natural killer cells against rituximab sensitive and resistant Burkitt lymphoma (BL).
Authors
Yaya Chu
New York Medical College, Valhalla, NY
Yaya Chu, Nang Kham Su, Sarah Alter, Emily Jeng, Peter R. Rhode, Matthew John Barth, Dean Anthony Lee, Hing C. Wong, Mitchell S. Cairo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B
Track
Developmental Therapeutics,Genitourinary Cancer,Head and Neck Cancer,Lung Cancer,Melanoma/Skin Cancers,Gastrointestinal Cancer,Breast and Gynecologic Cancers,Combination Studies,Implications for Patients and Society,Miscellaneous Cancers,Oncolytic Viruses,Hematologic Malignancies
Sub Track
Cell Therapies
Citation
J Clin Oncol 36, 2018 (suppl 5S; abstr 32)
DOI
10.1200/JCO.2018.36.5_suppl.32
Abstract #
32
Poster Bd #
C9
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Effect of CD137 stimulation on ibrutinib antagonism of GA101 dependent NK cell-mediated cytotoxicity.
First Author: Narendiran Rajasekaran
Poster
2015 ASCO Annual Meeting
CD137 co-stimulation and blocking PD-1 enhances NK cell-mediated target cell lysis by CD30/CD16A TandAb AFM13.
First Author: Xing Zhao
Poster
2013 ASCO Annual Meeting
AFM11, a CD19/CD3 bispecific tandab, to facilitate T-cell-mediated killing of CD19+ cells.
First Author: Eugene Zhukovsky
Poster
2011 ASCO Annual Meeting
A phase II randomized study of lenalidomide or lenalidomide and rituximab as maintenance therapy following standard chemotherapy for patients with high/high-intermediate risk diffuse large B-cell lymphoma.
First Author: N. M. Reddy